| Basics |
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals Inc is a biotechnology company. It is engaged in the development of medicine to treat diseases such as hepatitis B, and thrombosis with a genetic origin, primarily divided by the overproduction of one or more proteins.
|
| IPO Date: |
July 6, 2000 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.93B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.45 | 3.25%
|
| Avg Daily Range (30 D): |
$0.45 | 3.69%
|
| Avg Daily Range (90 D): |
$0.47 | 3.05%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.77M |
| Avg Daily Volume (30 D): |
1.75M |
| Avg Daily Volume (90 D): |
1.5M |
| Trade Size |
| Avg Trade Size (Sh.): |
125 |
| Avg Trade Size (Sh.) (30 D): |
70 |
| Avg Trade Size (Sh.) (90 D): |
70 |
| Institutional Trades |
| Total Inst.Trades: |
4,798 |
| Avg Inst. Trade: |
$3.18M |
| Avg Inst. Trade (30 D): |
$2.22M |
| Avg Inst. Trade (90 D): |
$4.19M |
| Avg Inst. Trade Volume: |
.11M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$5.41M |
| Avg Closing Trade (30 D): |
$3.09M |
| Avg Closing Trade (90 D): |
$5.18M |
| Avg Closing Volume: |
175.33K |
|
|
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$-1.22
|
$2.78
|
$-1.25
|
|
Diluted EPS
|
$-1.23
|
$2.75
|
$-1.23
|
|
Revenue
|
$ 545.21M
|
$ 542.71M
|
$ 2.5M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -154.68M
|
$ 367.86M
|
$ -175.22M
|
|
Operating Income / Loss
|
$ -118.55M
|
$ 381.2M
|
$ -161.41M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 58.01M
|
$
|
$
|
|
PE Ratio
|
|
|
|
| Splits |
| Nov 17, 2011:
10:1
|
| Jan 15, 2004:
65:1
|
|
